

Daniel C Javitt

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8479480/publications.pdf>

Version: 2024-02-01

118
papers

11,871
citations

30047

54
h-index

28275

105
g-index

120
all docs

120
docs citations

120
times ranked

9812
citing authors

#	ARTICLE	IF	CITATIONS
1	Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. <i>Trends in Neurosciences</i> , 2008, 31, 234-242.	4.2	896
2	Ketamine-Induced Deficits in Auditory and Visual Context-Dependent Processing in Healthy Volunteers. <i>Archives of General Psychiatry</i> , 2000, 57, 1139.	13.8	552
3	Glutamate and Schizophrenia: Phencyclidine, N-Methyl-D-Aspartate Receptors, and Dopamine-Glutamate Interactions. <i>International Review of Neurobiology</i> , 2007, 78, 69-108.	0.9	463
4	Automated analysis of free speech predicts psychosis onset in high-risk youths. <i>NPJ Schizophrenia</i> , 2015, 1, 15030.	2.0	453
5	When Doors of Perception Close: Bottom-up Models of Disrupted Cognition in Schizophrenia. <i>Annual Review of Clinical Psychology</i> , 2009, 5, 249-275.	6.3	441
6	The Spectrotemporal Filter Mechanism of Auditory Selective Attention. <i>Neuron</i> , 2013, 77, 750-761.	3.8	399
7	Somatosensory Input to Auditory Association Cortex in the Macaque Monkey. <i>Journal of Neurophysiology</i> , 2001, 85, 1322-1327.	0.9	368
8	N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: The final common pathway on the road to schizophrenia?. <i>Brain Research Bulletin</i> , 2010, 83, 108-121.	1.4	340
9	Early-Stage Visual Processing and Cortical Amplification Deficits in Schizophrenia. <i>Archives of General Psychiatry</i> , 2005, 62, 495.	13.8	325
10	Auditory dysfunction in schizophrenia: integrating clinical and basic features. <i>Nature Reviews Neuroscience</i> , 2015, 16, 535-550.	4.9	312
11	Sensory Processing Dysfunction in the Personal Experience and Neuronal Machinery of Schizophrenia. <i>American Journal of Psychiatry</i> , 2015, 172, 17-31.	4.0	306
12	Subcortical visual dysfunction in schizophrenia drives secondary cortical impairments. <i>Brain</i> , 2007, 130, 417-430.	3.7	291
13	Neurophysiological biomarkers for drug development in schizophrenia. <i>Nature Reviews Drug Discovery</i> , 2008, 7, 68-83.	21.5	283
14	Has an Angel Shown the Way? Etiological and Therapeutic Implications of the PCP/NMDA Model of Schizophrenia. <i>Schizophrenia Bulletin</i> , 2012, 38, 958-966.	2.3	268
15	Associated deficits in mismatch negativity generation and tone matching in schizophrenia. <i>Clinical Neurophysiology</i> , 2000, 111, 1733-1737.	0.7	255
16	Deficits in Auditory and Visual Context-Dependent Processing in Schizophrenia. <i>Archives of General Psychiatry</i> , 2000, 57, 1131.	13.8	210
17	Impaired mismatch negativity (MMN) generation in schizophrenia as a function of stimulus deviance, probability, and interstimulus/interdeviant interval. <i>Electroencephalography and Clinical Neurophysiology - Evoked Potentials</i> , 1998, 108, 143-153.	2.0	197
18	Sensory Contributions to Impaired Prosodic Processing in Schizophrenia. <i>Biological Psychiatry</i> , 2005, 58, 56-61.	0.7	189

#	ARTICLE	IF	CITATIONS
19	Impaired precision, but normal retention, of auditory sensory ("echoic") memory information in schizophrenia. <i>Journal of Abnormal Psychology</i> , 1997, 106, 315-324.	2.0	184
20	Magnocellular Pathway Impairment in Schizophrenia: Evidence from Functional Magnetic Resonance Imaging. <i>Journal of Neuroscience</i> , 2008, 28, 7492-7500.	1.7	183
21	A Roadmap for the Development and Validation of Event-Related Potential Biomarkers in Schizophrenia Research. <i>Biological Psychiatry</i> , 2011, 70, 28-34.	0.7	163
22	Auditory Sensory Dysfunction in Schizophrenia. <i>Archives of General Psychiatry</i> , 2000, 57, 1149.	13.8	156
23	Demonstration of mismatch negativity in the monkey. <i>Electroencephalography and Clinical Neurophysiology</i> , 1992, 83, 87-90.	0.3	155
24	Translating Glutamate: From Pathophysiology to Treatment. <i>Science Translational Medicine</i> , 2011, 3, 102mr2.	5.8	147
25	Glutamatergic abnormalities in schizophrenia: A review of proton MRS findings. <i>Schizophrenia Research</i> , 2014, 152, 325-332.	1.1	144
26	Impairments in generation of early-stage transient visual evoked potentials to magno- and parvocellular-selective stimuli in schizophrenia. <i>Clinical Neurophysiology</i> , 2005, 116, 2204-2215.	0.7	132
27	Getting the Cue: Sensory Contributions to Auditory Emotion Recognition Impairments in Schizophrenia. <i>Schizophrenia Bulletin</i> , 2010, 36, 545-556.	2.3	129
28	D-serine for the treatment of negative symptoms in individuals at clinical high risk of schizophrenia: a pilot, double-blind, placebo-controlled, randomised parallel group mechanistic proof-of-concept trial. <i>Lancet Psychiatry</i> , 2015, 2, 403-412.	3.7	128
29	The Neural Substrates of Impaired Prosodic Detection in Schizophrenia and Its Sensorial Antecedents. <i>American Journal of Psychiatry</i> , 2007, 164, 474-482.	4.0	122
30	Early Sensory Contributions to Contextual Encoding Deficits in Schizophrenia. <i>Archives of General Psychiatry</i> , 2011, 68, 654.	13.8	122
31	Magnocellular and parvocellular contributions to backward masking dysfunction in schizophrenia. <i>Schizophrenia Research</i> , 2003, 64, 91-101.	1.1	121
32	“It’s not what you say, but how you say it”: a reciprocal temporo-frontal network for affective prosody. <i>Frontiers in Human Neuroscience</i> , 2010, 4, 19.	1.0	108
33	Predictive Suppression of Cortical Excitability and Its Deficit in Schizophrenia. <i>Journal of Neuroscience</i> , 2013, 33, 11692-11702.	1.7	106
34	Reading impairment and visual processing deficits in schizophrenia. <i>Schizophrenia Research</i> , 2006, 87, 238-245.	1.1	101
35	Reversal of Phencyclidine-Induced Dopaminergic Dysregulation by N-Methyl-D-Aspartate Receptor/Glycine-site Agonists. <i>Neuropsychopharmacology</i> , 2004, 29, 300-307.	2.8	100
36	Auditory Emotion Recognition Impairments in Schizophrenia: Relationship to Acoustic Features and Cognition. <i>American Journal of Psychiatry</i> , 2012, 169, 424-432.	4.0	99

#	ARTICLE	IF	CITATIONS
37	Twenty-five Years of Glutamate in Schizophrenia: Are We There Yet?. Schizophrenia Bulletin, 2012, 38, 911-913.	2.3	98
38	Reading Deficits in Schizophrenia and Individuals at High Clinical Risk: Relationship to Sensory Function, Course of Illness, and Psychosocial Outcome. American Journal of Psychiatry, 2014, 171, 949-959.	4.0	98
39	Thinking Glutamatergically: Changing Concepts of Schizophrenia Based Upon Changing Neurochemical Models. Clinical Schizophrenia and Related Psychoses, 2010, 4, 189-200.	1.4	98
40	Neurocognitive and symptom correlates of daily problem-solving skills in schizophrenia. Schizophrenia Research, 2006, 83, 237-245.	1.1	88
41	Improvement in mismatch negativity generation during d-serine treatment in schizophrenia: Correlation with symptoms. Schizophrenia Research, 2018, 191, 70-79.	1.1	88
42	Utility of Imaging-Based Biomarkers for Glutamate-Targeted Drug Development in Psychotic Disorders. JAMA Psychiatry, 2018, 75, 11.	6.0	88
43	Consequences of Magnocellular Dysfunction on Processing Attended Information in Schizophrenia. Cerebral Cortex, 2012, 22, 1282-1293.	1.6	84
44	Neurophysiological mechanisms of cortical plasticity impairments in schizophrenia and modulation by the NMDA receptor agonist D-serine. Brain, 2016, 139, 3281-3295.	3.7	84
45	Neural Substrates of Auditory Emotion Recognition Deficits in Schizophrenia. Journal of Neuroscience, 2015, 35, 14909-14921.	1.7	80
46	Mismatch negativity as a biomarker of theta band oscillatory dysfunction in schizophrenia. Schizophrenia Research, 2018, 191, 51-60.	1.1	79
47	Is the glycine site half saturated or half unsaturated? Effects of glutamatergic drugs in schizophrenia patients. Current Opinion in Psychiatry, 2006, 19, 151-157.	3.1	78
48	Differential Relationships of Mismatch Negativity and Visual P1 Deficits to Premorbid Characteristics and Functional Outcome in Schizophrenia. Biological Psychiatry, 2012, 71, 521-529.	0.7	76
49	Loneliness in schizophrenia and its possible correlates. An exploratory study. Psychiatry Research, 2016, 246, 211-217.	1.7	72
50	Theory of Mind (ToM) and counterfactuality deficits in schizophrenia: misperception or misinterpretation?. Psychological Medicine, 2006, 36, 1075-1083.	2.7	69
51	Neurophysiological models for new treatment development in schizophrenia: early sensory approaches. Annals of the New York Academy of Sciences, 2015, 1344, 92-104.	1.8	64
52	Replacing DSM Categorical Analyses With Dimensional Analyses in Psychiatry Research. JAMA Psychiatry, 2015, 72, 1159.	6.0	64
53	Meta-analysis of mismatch negativity to simple versus complex deviants in schizophrenia. Schizophrenia Research, 2018, 191, 25-34.	1.1	64
54	Understanding tDCS effects in schizophrenia: a systematic review of clinical data and an integrated computation modeling analysis. Expert Review of Medical Devices, 2014, 11, 383-394.	1.4	61

#	ARTICLE	IF	CITATIONS
55	Reduction in Tonal Discriminations Predicts Receptive Emotion Processing Deficits in Schizophrenia and Schizoaffective Disorder. <i>Schizophrenia Bulletin</i> , 2013, 39, 86-93.	2.3	59
56	The Thalamocortical Circuit of Auditory Mismatch Negativity. <i>Biological Psychiatry</i> , 2020, 87, 770-780.	0.7	58
57	The past and future of novel, non-dopamine-2 receptor therapeutics for schizophrenia: A critical and comprehensive review. <i>Journal of Psychiatric Research</i> , 2019, 108, 57-83.	1.5	54
58	Continuous Phencyclidine Treatment Induces Schizophrenia-Like Hyperreactivity of Striatal Dopamine Release. <i>Neuropsychopharmacology</i> , 2001, 25, 157-164.	2.8	52
59	Differential Patterns of Visual Sensory Alteration Underlying Face Emotion Recognition Impairment and Motion Perception Deficits in Schizophrenia and Autism Spectrum Disorder. <i>Biological Psychiatry</i> , 2019, 86, 557-567.	0.7	51
60	A roadmap for development of neuro-oscillations as translational biomarkers for treatment development in neuropsychopharmacology. <i>Neuropsychopharmacology</i> , 2020, 45, 1411-1422.	2.8	51
61	Contributions of early cortical processing and reading ability to functional status in individuals at clinical high risk for psychosis. <i>Schizophrenia Research</i> , 2015, 164, 1-7.	1.1	46
62	Ventromedial prefrontal cortex/anterior cingulate cortex Glx, glutamate, and GABA levels in medication-free major depressive disorder. <i>Translational Psychiatry</i> , 2021, 11, 419.	2.4	45
63	Rodent Mismatch Negativity/theta Neuro-Oscillatory Response as a Translational Neurophysiological Biomarker for N-Methyl-D-Aspartate Receptor-Based New Treatment Development in Schizophrenia. <i>Neuropsychopharmacology</i> , 2018, 43, 571-582.	2.8	44
64	Pupillometer-based neurofeedback cognitive training to improve processing speed and social functioning in individuals at clinical high risk for psychosis.. <i>Psychiatric Rehabilitation Journal</i> , 2017, 40, 33-42.	0.8	43
65	Significant improvement in treatment resistant auditory verbal hallucinations after 5 days of double-blind, randomized, sham controlled, fronto-temporal, transcranial direct current stimulation (tDCS): A replication/extension study. <i>Brain Stimulation</i> , 2019, 12, 981-991.	0.7	39
66	Impaired magnocellular/dorsal stream activation predicts impaired reading ability in schizophrenia. <i>NeuroImage: Clinical</i> , 2013, 2, 8-16.	1.4	37
67	Neurofilament light interaction with GluN1 modulates neurotransmission and schizophrenia-associated behaviors. <i>Translational Psychiatry</i> , 2018, 8, 167.	2.4	37
68	Impaired Motion Processing in Schizophrenia and the Attenuated Psychosis Syndrome: Etiological and Clinical Implications. <i>American Journal of Psychiatry</i> , 2018, 175, 1243-1254.	4.0	35
69	Sensory and cross-network contributions to response inhibition in patients with schizophrenia. <i>NeuroImage: Clinical</i> , 2018, 18, 31-39.	1.4	34
70	Abnormal task modulation of oscillatory neural activity in schizophrenia. <i>Frontiers in Psychology</i> , 2013, 4, 540.	1.1	33
71	Neural oscillatory deficits in schizophrenia predict behavioral and neurocognitive impairments. <i>Frontiers in Human Neuroscience</i> , 2015, 9, 371.	1.0	32
72	A tale of two sites: Differential impairment of frequency and duration mismatch negativity across a primarily inpatient versus a primarily outpatient site in schizophrenia. <i>Schizophrenia Research</i> , 2018, 191, 10-17.	1.1	32

#	ARTICLE	IF	CITATIONS
73	Targeted Treatment of Individuals With Psychosis Carrying a Copy Number Variant Containing a Genomic Triplication of the Glycine Decarboxylase Gene. <i>Biological Psychiatry</i> , 2019, 86, 523-535.	0.7	32
74	Proof of mechanism and target engagement of glutamatergic drugs for the treatment of schizophrenia: RCTs of pomaglumed and TS-134 on ketamine-induced psychotic symptoms and pharmacOBOLD in healthy volunteers. <i>Neuropsychopharmacology</i> , 2020, 45, 1842-1850.	2.8	32
75	Inflammatory biomarkers in psychosis and clinical high risk populations. <i>Schizophrenia Research</i> , 2019, 206, 440-443.	1.1	30
76	Impact of baseline early auditory processing on response to cognitive remediation for schizophrenia. <i>Schizophrenia Research</i> , 2019, 208, 397-405.	1.1	30
77	Double blind, two dose, randomized, placebo-controlled, cross-over clinical trial of the positive allosteric modulator at the alpha7 nicotinic cholinergic receptor AVL-3288 in schizophrenia patients. <i>Neuropsychopharmacology</i> , 2020, 45, 1339-1345.	2.8	30
78	Mismatch negativity (MMN) to spatial deviants and behavioral spatial discrimination ability in the etiology of auditory verbal hallucinations and thought disorder in schizophrenia. <i>Schizophrenia Research</i> , 2018, 191, 140-147.	1.1	29
79	Differential profiles in auditory social cognition deficits between adults with autism and schizophrenia spectrum disorders: A preliminary analysis. <i>Journal of Psychiatric Research</i> , 2016, 79, 21-27.	1.5	28
80	Bimodal distribution of tone-matching deficits indicates discrete pathophysiological entities within the syndrome of schizophrenia. <i>Translational Psychiatry</i> , 2019, 9, 221.	2.4	28
81	Hierarchical deficits in auditory information processing in schizophrenia. <i>Schizophrenia Research</i> , 2019, 206, 135-141.	1.1	28
82	A multicenter study of ketamine effects on functional connectivity: Large scale network relationships, hubs and symptom mechanisms. <i>NeuroImage: Clinical</i> , 2019, 22, 101739.	1.4	27
83	Fractal Dimension Analysis of Subcortical Gray Matter Structures in Schizophrenia. <i>PLoS ONE</i> , 2016, 11, e0155415.	1.1	27
84	Glycine modulators in schizophrenia. <i>Current Opinion in Investigational Drugs</i> , 2002, 3, 1067-72.	2.3	27
85	Mismatch negativity: A simple and useful biomarker of N-methyl-d-aspartate receptor (NMDAR)-type glutamate dysfunction in schizophrenia. <i>Schizophrenia Research</i> , 2018, 191, 1-4.	1.1	26
86	Targeting glutamate to treat schizophrenia: lessons from recent clinical studies. <i>Psychopharmacology</i> , 2016, 233, 2425-2428.	1.5	22
87	Effects of acute N-acetylcysteine challenge on cortical glutathione and glutamate in schizophrenia: A pilot in vivo proton magnetic resonance spectroscopy study. <i>Psychiatry Research</i> , 2019, 275, 78-85.	1.7	21
88	Developmental trajectory of mismatch negativity and visual event-related potentials in healthy controls: Implications for neurodevelopmental vs. neurodegenerative models of schizophrenia. <i>Schizophrenia Research</i> , 2018, 191, 101-108.	1.1	17
89	Deficits and compensation: Attentional control cortical networks in schizophrenia. <i>NeuroImage: Clinical</i> , 2020, 27, 102348.	1.4	17
90	The importance of a good night's sleep: An open-label trial of the sodium salt of $\hat{1}^3$ -hydroxybutyric acid in insomnia associated with schizophrenia. <i>Schizophrenia Research</i> , 2010, 120, 225-226.	1.1	16

#	ARTICLE	IF	CITATIONS
91	Implicit emotion perception in schizophrenia. <i>Journal of Psychiatric Research</i> , 2015, 71, 112-119.	1.5	16
92	Auditory tasks for assessment of sensory function and affective prosody in schizophrenia. <i>Comprehensive Psychiatry</i> , 2014, 55, 1862-1874.	1.5	15
93	Current and Emergent Treatments for Symptoms and Neurocognitive Impairment in Schizophrenia. <i>Current Treatment Options in Psychiatry</i> , 2014, 1, 107-120.	0.7	15
94	Neural and functional correlates of impaired reading ability in schizophrenia. <i>Scientific Reports</i> , 2019, 9, 16022.	1.6	15
95	A century of sensory processing dysfunction in schizophrenia. <i>European Psychiatry</i> , 2019, 59, 77-79.	0.1	15
96	Failure to engage the temporoparietal junction/posterior superior temporal sulcus predicts impaired naturalistic social cognition in schizophrenia. <i>Brain</i> , 2021, 144, 1898-1910.	3.7	14
97	Immediate affective motivation is not impaired in schizophrenia. <i>Schizophrenia Research</i> , 2014, 159, 157-163.	1.1	13
98	The glutamate/N-methyl-d-aspartate receptor (NMDAR) model of schizophrenia at 35: On the path from syndrome to disease. <i>Schizophrenia Research</i> , 2022, 242, 56-61.	1.1	12
99	Biotypes in Psychosis: Has the RDoC Era Arrived?. <i>American Journal of Psychiatry</i> , 2016, 173, 313-314.	4.0	11
100	What you see is what you get: visual scanning failures of naturalistic social scenes in schizophrenia. <i>Psychological Medicine</i> , 2021, 51, 2923-2932.	2.7	11
101	Neurophysiological, Oculomotor, and Computational Modeling of Impaired Reading Ability in Schizophrenia. <i>Schizophrenia Bulletin</i> , 2021, 47, 97-107.	2.3	11
102	Complementary fMRI and EEG evidence for more efficient neural processing of rhythmic vs. unpredictably timed sounds. <i>Frontiers in Psychology</i> , 2015, 6, 1663.	1.1	10
103	Deficits in Pre-attentive Processing of Spatial Location and Negative Symptoms in Subjects at Clinical High Risk for Schizophrenia. <i>Frontiers in Psychiatry</i> , 2020, 11, 629144.	1.3	10
104	Mismatch negativity as an index of target engagement for excitation/inhibition-based treatment development: a double-blind, placebo-controlled, randomized, single-dose cross-over study of the serotonin type-3 receptor antagonist CVN058. <i>Neuropsychopharmacology</i> , 2022, 47, 711-718.	2.8	10
105	Are basic auditory processes involved in source-monitoring deficits in patients with schizophrenia?. <i>Schizophrenia Research</i> , 2019, 210, 135-142.	1.1	8
106	Translational neurophysiological biomarkers of N-methyl-d-aspartate receptor dysfunction in serine racemase knockout mice. <i>Biomarkers in Neuropsychiatry</i> , 2020, 2, 100019.	0.7	8
107	Reply: A few remarks on assessing magnocellular sensitivity in patients with schizophrenia. <i>Brain</i> , 2007, 130, e84-e84.	3.7	7
108	Computational modeling of excitatory/inhibitory balance impairments in schizophrenia. <i>Schizophrenia Research</i> , 2022, 249, 47-55.	1.1	7

#	ARTICLE	IF	CITATIONS
109	Bitopertin in schizophrenia: glass half full?. <i>Lancet Psychiatry</i> , 2016, 3, 1092-1093.	3.7	6
110	Impaired Fixation-Related Theta Modulation Predicts Reduced Visual Span and Guided Search Deficits in Schizophrenia. <i>Cerebral Cortex</i> , 2020, 30, 2823-2833.	1.6	6
111	What can the study of first impressions tell us about attitudinal ambivalence and paranoia in schizophrenia?. <i>Psychiatry Research</i> , 2016, 238, 86-92.	1.7	5
112	Efficacy of Transcranial Direct Current Stimulation to Improve Insight in Patients With Schizophrenia: A Systematic Review and Meta-analysis of Randomized Controlled Trials. <i>Schizophrenia Bulletin</i> , 2022, 48, 1284-1294.	2.3	5
113	Excitatory Amino Acids in Schizophrenia: Both What You Have, and What You Do With Them. <i>Biological Psychiatry</i> , 2018, 83, 470-472.	0.7	4
114	Relationships between Diffusion Tensor Imaging and Resting State Functional Connectivity in Patients with Schizophrenia and Healthy Controls: A Preliminary Study. <i>Brain Sciences</i> , 2022, 12, 156.	1.1	3
115	The characteristics of cognitive neuroscience tests in a schizophrenia cognition clinical trial: Psychometric properties and correlations with standard measures. <i>Schizophrenia Research: Cognition</i> , 2020, 19, 100161.	0.7	2
116	Translational Mechanistic Biomarkers for the 21st Century. <i>American Journal of Psychiatry</i> , 2021, 178, 893-895.	4.0	1
117	Madness in the garden or worm in the apple?. <i>Trends in Cognitive Sciences</i> , 2002, 6, 187.	4.0	0
118	Computational mapping of brain networks. , 2016, , .		0